Human T cells are central effectors of immunity and cancer immunotherapy. CRISPR-based
functional studies in T cells could prioritize novel targets for drug development and improve …

T-cell genome engineering holds great promise for cell-based therapies for cancer, HIV,
primary immune deficiencies, and autoimmune diseases, but genetic manipulation of human T …

Decades of work have aimed to genetically reprogram T cells for therapeutic purposes 1 , 2
using recombinant viral vectors, which do not target transgenes to specific genomic sites 3 , …

The majority of genetic variants associated with common human diseases map to enhancers,
non-coding elements that shape cell-type-specific transcriptional programs and responses …

T cell exhaustion limits antitumor immunity, but the molecular determinants of this process
remain poorly understood. Using a chronic stimulation assay, we performed genome-wide …

Genome-wide association studies have identified loci underlying human diseases, but the
causal nucleotide changes and mechanisms remain largely unknown. Here we developed a …

Adoptive transfer of genetically modified immune cells holds great promise for cancer
immunotherapy. CRISPR knockin targeting can improve cell therapies, but more high-throughput …

Host proteins are essential for HIV entry and replication and can be important nonviral
therapeutic targets. Large-scale RNA interference (RNAi)-based screens have identified nearly a …

Versatile and precise genome modifications are needed to create a wider range of adoptive
cellular therapies 1 , 2 , 3 , 4 – 5 . Here we report two improvements that increase the …

MicroRNAs (miRNAs) are crucial for normal embryonic stem (ES) cell self-renewal and
cellular differentiation, but how miRNA gene expression is controlled by the key transcriptional …